Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 20

15:05 EDT 22nd June 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 476–500 of 6,400+

Probably Relevant

Karus Therapeutics CEO Simon Kerry discusses the company's focus on PI3 Kinase and HDAC6 inhibitor programmes.

Simon Kerry the CEO of the Oxfordshire based company Karus Therapeutics, talks with Fintan Walton about the company's work to develop innovative medicines for the treatment of inflammatory disease and cancer.


Global Outlook for the Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022 – Rising Number of Patients Opting for Chemotherapy – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022. The report has been prepared based on an … Continue reading → Cet article Globa...

Orchard Therapeutics receives Rare Pediatric Disease Designation from FDA

Orchard Therapeutics, a commercial stage company, has been granted a Rare Pediatric Disease Designation from the US Food and Drug Administration (FDA) for its gene therapy candidate, OTL-200, for the treatment of patients with MLD


Sarepta Therapeutics-Aktie: weitere Outperformance trotz Kurssteigerungen!

Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse des Analysten Brian Abrahams von RBC Capital Markets: Analyst Brian Abrahams vom Investmenthaus RBC Capital Markets bestätigt laut ...

Unum Therapeutics IPO Raises $69M to Test Universal Cell Therapies

Unum Therapeutics is the latest biotechnology company to take the plunge into the public markets, raising $69.2 million that it plans to use to fund more clinical tests of its experimental cancer treatments. The Cambridge, MA, company priced its initial public stock offering of 5.77 million shares at $12 each, which was on the low […]

Syndesi Therapeutics launches with €17mm Series A

Syndesi Therapeutics SA (cognitive disorders) has launched with a €17mm ($21mm) Series A round from an investor syndicate c...

Phanes Therapeutics selects CrownBio to advance oncology drug pipeline

Global drug discovery and development services company, Crown Bioscience, has been selected as a strategic partner by Phanes Therapeutics to accelerate the discovery and development of novel oncology agents.

Eidos Therapeutics Closes on Series B Round Worth $64M

Eidos Therapeutics closed on a $64 million Series B financing round. The funds will be used to advance the company’s product candidate, AG10, into Phase II clinical trials and Phase III trials.

Global and Chinese Acute Heart Failure AHF Therapeutics Industry, 2017 Market Research Report [Report Updated: 21122017] Prices from USD $3000

The 'Global and Chinese Acute Heart Failure AHF Therapeutics Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Acute Heart Failure AHF Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Acute Heart Failure AHF Therapeutics manufacturers and is a valuable source of g...

Global and Chinese Coronary Artery Disease Therapeutics Industry, 2017 Market Research Report [Report Updated: 23122017] Prices from USD $3000

The 'Global and Chinese Coronary Artery Disease Therapeutics Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Coronary Artery Disease Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Coronary Artery Disease Therapeutics manufacturers and is a valuable source of g...

Global and Chinese Acute Ischemic Stroke Therapeutics Industry, 2017 Market Research Report [Report Updated: 23122017] Prices from USD $3000

The 'Global and Chinese Acute Ischemic Stroke Therapeutics Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Acute Ischemic Stroke Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Acute Ischemic Stroke Therapeutics manufacturers and is a valuable source of guidanc...

Global and Chinese Duchenne Muscular Dystrophy Therapeutics Industry, 2017 Market Research Report [Report Updated: 19122017] Prices from USD $3000

The 'Global and Chinese Duchenne Muscular Dystrophy Therapeutics Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Duchenne Muscular Dystrophy Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Duchenne Muscular Dystrophy Therapeutics manufacturers and is a valuable...

Global and Chinese Kidney Transplant Rejection Therapeutics Industry, 2017 Market Research Report [Report Updated: 24122017] Prices from USD $3000

The 'Global and Chinese Kidney Transplant Rejection Therapeutics Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Kidney Transplant Rejection Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Kidney Transplant Rejection Therapeutics manufacturers and is a valuable...

Active-Investors: Wired News - Voyager Therapeutics Signs Global Collaboration Agreement with AbbVie to Develop New Treatments for Tau-Related Neuro-Degenerative Diseases

Stock Monitor: Bioverativ Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: ...

Therapeutics and collaboration in the spotlight at Technology Showcase

This year’s Technology Showcase, held on 13 June at Oxford’s Saïd Business School, attracted a host of leading academics, clinicians and investors to discuss the most exciting commercial opportunities and projects in the field of Therapeutics, Small Molecules and Biologics. The event, which was attended by around 200 people, was organised by the NIHR Oxford BRC, ... Read more

Spark Therapeutics reveals payment options for its one-time treatment of a rare retinal disease

US-based company, Spark Therapeutics, has announced a programme of improved access to its one-time gene therapy treatment, LUXTURNA, indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy

Cardiol Therapeutics Closes CDN$10.5 Million Private Placement

Cardiol Therapeutics Inc. ("Cardiol" or the "Company"), a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart, is pleased to announce the successful closing of a brokered private placement (the "Private Placement") of approximately CDN$10.5 million princi...

Topas Therapeutics will be translational partner for CRC focused on liver inflammation

Topas Therapeutics, a German-based platform company, will serve as the exclusive translational partner for the recently extended Collaborative Research Center (CRC) 841, ‘Liver inflammation: infection, immune regulation and consequences’.

Active-Investors: Wired News - Seattle Genetics to Acquire Cascadian Therapeutics

Stock Monitor: Cascadian Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 02, 2018 / Active-Investors.com has just released a free research report on Seattle Genetics, Inc. (...

Expansion Therapeutics raised $55.3mm via Series A

Expansion Therapeutics Inc. (developing RNA-targeted small-molecule therapies) raised $55.3mm in its Series A financing co-le...

Menlo Therapeutics Series B round brings in $45mm

Dermatology-focused start-up Menlo Therapeutics Inc. (formerly Tigercat Pharma) raised $45mm in a Series B round led by Vivo ...

Menlo Therapeutics' Series B round brings in $45mm

Dermatology-focused start-up Menlo Therapeutics Inc. (formerly Tigercat Pharma) raised $45mm in a Series B round led by Vivo ...

SpringWorks Therapeutics to Present at Cowen and Company’s 38th Annual Health Care Conference

SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, today announced that the Company will present at the Cowen and Company 38th Annual Health Care Conference. SpringWorks Therapeutics’ President and Founder Lara S. Sullivan, M.D., is scheduled ...

Cesca Therapeutics Announces First Quarter 2018 Financial Results and Provides Corporate Update

Cesca Therapeutics (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced financial and operating results for the first quarter ended March 31, 2018, and provided a corporate update. As quoted in the press release: “Since our acquisition of SynGen in July of last year, we have made substantial progress … Continued The...

Summit Therapeutics to participate in BTIG Healthcare Conference

Drug discovery and development company Summit Therapeutics announced on Friday that its management would participate in one-on-one meetings at the 2018 BTIG Healthcare Conference. The AIM-traded fi...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks